VENUS REMEDIES
Back to Income Statement
|
VENUS REMEDIES Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹648 Cr | ₹601 Cr | ₹556 Cr | ₹600 Cr | ₹548 Cr |
What is the latest Revenue of VENUS REMEDIES ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹648 Cr |
| Mar2024 | ₹601 Cr |
| Mar2023 | ₹556 Cr |
| Mar2022 | ₹600 Cr |
| Mar2021 | ₹548 Cr |
How is Revenue of VENUS REMEDIES Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹648 Cr | 7.72 | |
| Mar2024 | ₹601 Cr | 8.27 | |
| Mar2023 | ₹556 Cr | -7.44 | |
| Mar2022 | ₹600 Cr | 9.50 | |
| Mar2021 | ₹548 Cr | - | |
Compare Revenue of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹2,529.5 Cr | 17.8% | 100.9% | 308.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,428.0 Cr | 1.5% | -3% | 6.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,426.0 Cr | -2.2% | -4.5% | 0.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,603.0 Cr | 0.8% | 2.3% | 43.9% | Stock Analytics | |
| CIPLA | ₹111,604.0 Cr | 0.4% | -4% | -7.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,775.0 Cr | 0.8% | -1.8% | -3.4% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | 17.8% |
100.9% |
308.4% |
| SENSEX | 3.7% |
2.2% |
-7.2% |
You may also like the below Video Courses